Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Why Coherus BioSciences Stock Soared Today
05:43pm, Monday, 30'th Oct 2023
Coherus and Chinese partner Junshi Biosciences announced U.S. FDA approval of Loqtorzi in all lines of treatment for nasopharyngeal carcinoma (NPC). Coherus management has insisted they will "not enga
Why Coherus BioSciences Stock Popped Today
04:45pm, Thursday, 05'th Oct 2023
Coherus announced it has resubmitted a biologic license application for one of its products. The FDA had previously issued a complete response letter holding up the product's approval, citing an ongoi
Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down
12:01pm, Tuesday, 26'th Sep 2023
Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.
Coherus BioSciences' new injector treatment for cancer patients rejected by FDA
08:53am, Monday, 25'th Sep 2023
Coherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a treatment designed to cut cancer patients' r
Why Coherus BioSciences Stock Was Plunging This Week
08:31am, Friday, 08'th Sep 2023
It is about to be deleted from a popular small-cap equity index. As of Monday, Sept.
Coherus BioSciences to Participate at Upcoming September Investor Conferences
04:01pm, Friday, 01'st Sep 2023
REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor confe
Why Coherus BioSciences Stock Popped Today
07:43pm, Thursday, 03'rd Aug 2023
The immuno-oncology biotech specialist delivered stronger-than-expected revenue and earnings in Q2. Coherus also reiterated its full-year guidance and anticipates closing on its pending merger with Su
Coherus BioSciences, Inc. (CHRS) Q2 2023 Earnings Call Transcript
11:35pm, Wednesday, 02'nd Aug 2023
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Marek Ciszewski – Senior Vice President-Investor Relations Denny Lanfear –
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
06:43pm, Wednesday, 02'nd Aug 2023
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
3 Hot Penny Stocks To Watch After TUP Stock Explodes, Again
01:48pm, Thursday, 27'th Jul 2023
Why would anyone want to buy penny stocks? They're extremely risky.
3 Hot Penny Stocks To Watch After TUP Stock Explodes, Again
01:48pm, Thursday, 27'th Jul 2023
Why would anyone want to buy penny stocks? They're extremely risky.
Best Penny Stocks To Buy Now? 3 To Watch Right Now
02:23pm, Friday, 07'th Jul 2023
Ever heard of penny stocks? If you're new to investing, you might be scratching your head.
Coherus: Why I Am Exiting, But Also Why You May Want To Hold On
12:40pm, Thursday, 06'th Jul 2023
Here, I discuss my reasons for exiting the stock. My reasons are more or less specific to my situation. Thus, we can agree to disagree without being too disagreeable about it.
Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
09:12am, Monday, 03'rd Jul 2023
Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of over 85% to the blockbuster arthritis drug.
Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences
11:01am, Friday, 16'th Jun 2023
Surface Oncology shares jumped by more than 16% on Friday morning after it was revealed the clinical-stage immuno-oncology (I-O) company is being acquired by Coherus BioSciences (NASDAQ:CHRS). The sto
